The benefit of radium-@ compared with placebo was seen in both docetaxel subgroups for most main secondary efficacy endpoints ; risk for time to time to first symptomatic skeletal event was reduced with radium-@ versus placebo in patients with previous docetaxel use , but the difference was not significant in those with no previous docetaxel use .